The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Critical Challenges in PD: Alpha-synuclein Neuroimaging, 200918F-labeled Alpha-Synuclein Ligands for PET Imaging of Lewy Bodies
Objective/Rationale:
The Avid-ProteoTech program aims at identifying radiopharmaceuticals for PET imaging of Lewy bodies in the human brain. Lewy bodies, formed by aggregates of alpha-synuclein, are a... -
Critical Challenges in PD: Alpha-synuclein Neuroimaging, 2009A Strategy to Develop a Radiotracer Targeting Alpha-Synuclein
Objective/Rationale:
Alpha-synuclein is a protein that is found in nerve cells of patients with PD and therefore provides a potential target for methods designed to monitor the disease process in PD... -
Rapid Response Innovation Awards, 2009H5N1 Influenza Virus as a Etiological Agent in Parkinson's Disease
Objective/Rationale:
There is a significant literature (mostly based on cases from the Spanish Influenza outbreak of 1918) that has documented Parkinson’s disease occurring, following exposure to... -
MJFF Research Grant, 2008Developing New Antibodies for a Standardized Alpha-Synuclein Assay (ELISA)
Objective/Rationale:
To raise and characterize new antibodies in vertebrate animals that allow for the routine measurement of a key protein linked to Parkinson disease, alpha-synuclein. A renewable... -
MJFF Research Grant, 2008Pharmacodynamic Biomarkers of Drug-induced Protein Clearance in Rodent Cerebrospinal Fluid
Objective/Rationale:
Parkinson’s disease is, at least in part, a disease caused by misfolding and aggregation of the protein alpha-synuclein. Boosting the natural degradation machinery of diseased... -
Improving Delivery of Parkinson's Disease Therapeutics to th, 2008Image-Guided Convective Delivery of AAV Vectors
Objective/Rationale:
Gene transfer technology holds promise to permanently alter the natural course of PD. However, in order for this technology to work there is a critical need for safe, reproducible...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.